Merck’s weight-loss pill deal: what it means for Eli Lilly
Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said ...
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...
Merck signs up to $2 billion deal for oral weight-loss drug with China's Hansoh
Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat ...
israelnewsonline1d
Eli Lilly is looking to extend its winning streak in the broad market to six years
Eli Lilly has surpassed that S&P 500 five years in a row when Wall Street recognized its enormous opportunity in obesity ...
Competition will make weight-loss drugs better, cheaper and bigger
Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...
BioSpace11d
Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal
The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...
Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results
Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...
Daily6d
Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market
Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...
NBC 10 Philadelphia11d
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck on Wednesday said it has snagged the rights to an experimental weight loss pill ... obesity pills that can compete with blockbuster injections from Novo Nordisk and Eli Lilly.